Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;29(5):288-294.
doi: 10.1007/s12471-020-01517-8. Epub 2020 Nov 17.

ONCOR: design of the Dutch cardio-oncology registry

J A M Kamphuis  1 , M Linschoten  1 , M J Cramer  1 , F Alsemgeest  2 , D J W van Kessel  3 , K Urgel  3 , M C Post  1   3 , O C Manintveld  4 , H C Hassing  4 , C Liesting  5 , A J Wardeh  6 , E G M Olde Bijvank  6 , J Schaap  7 , A M Stevense-den Boer  8 , P A Doevendans  1   9   10 , F W Asselbergs  1   10   11 , A J Teske  12
Affiliations

ONCOR: design of the Dutch cardio-oncology registry

J A M Kamphuis et al. Neth Heart J. 2021 May.

Abstract

Background: The relative new subspecialty 'cardio-oncology' was established to meet the growing demand for an interdisciplinary approach to the management of cancer therapy-related cardiovascular adverse events. In recent years, specialised cardio-oncology services have been implemented worldwide, which all strive to improve the cardiovascular health of cancer patients. However, limited data are currently available on the outcomes and experiences of these specialised services, and optimal strategies for cardio-oncological care have not been established.

Aim: The ONCOR registry has been created for prospective data collection and evaluation of cardio-oncological care in daily practice.

Methods: Dutch hospitals using a standardised cardio-oncology care pathway are included in this national, multicentre, observational cohort study. All patients visiting these cardio-oncology services are eligible for study inclusion. Data collection at baseline consists of the (planned) cancer treatment and the cardiovascular risk profile, which are used to estimate the cardiotoxic risk. Information regarding invasive and noninvasive tests is collected during the time patients receive cardio-oncological care. Outcome data consist of the incidence of cardiovascular complications and major adverse cardiac events, and the impact of these events on the oncological treatment.

Discussion: Outcomes of the ONCOR registry may aid in gaining more insight into the incidence of cancer therapy-related cardiovascular complications. The registry facilitates research on mechanisms of cardiovascular complications and on diagnostic, prognostic and therapeutic strategies. In addition, it provides a platform for future (interventional) studies. Centres with cardio-oncology services that are interested in contributing to the ONCOR registry are hereby invited to participate.

Keywords: Cardio-oncology; Registries; Research design.

PubMed Disclaimer

Conflict of interest statement

J.A.M. Kamphuis, M. Linschoten, M.J. Cramer, F. Alsemgeest, D.J.W. van Kessel, K. Urgel, M.C. Post, O.C. Manintveld, H.C. Hassing, C. Liesting, A.J. Wardeh, E.G.M. Olde Bijvank, J. Schaap, A.M. Stevense-den Boer, P.A. Doevendans, F.W. Asselbergs and A.J. Teske declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Cardiotoxicity risk score, adapted from [13]. The highest treatment-related risk score (e.g. 4, 2, 1 or 0) is used to calculate the score. For risk scores of individual anticancer agents and regimens, see ‘Medication risk score’ in Electronic Supplementary Material
Fig. 2
Fig. 2
Cancer therapy – related cardiovascular complications
Fig. 3
Fig. 3
Informed consent procedure and data collection. (CV cardiovascular, ECG electrocardiography. *In case patients agree, they can be approached for future studies)
See this image and copyright information in PMC

References

    1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2019;2019(69):363–385. doi: 10.3322/caac.21565. - DOI - PubMed
    1. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–796. doi: 10.1016/S1470-2045(07)70246-2. - DOI - PubMed
    1. Naaktgeboren WR, Linschoten M, de Graeff A, et al. Long-term cardiovascular health in adult cancer survivors. Maturitas. 2017;105:37–45. doi: 10.1016/j.maturitas.2017.05.014. - DOI - PubMed
    1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;2016(37):2768–2801. doi: 10.1093/eurheartj/ehw211. - DOI - PubMed
    1. Strongman H, Gadd S, Matthews A, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet. 2019;394:1041–1054. doi: 10.1016/S0140-6736(19)31674-5. - DOI - PMC - PubMed

LinkOut - more resources